<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The most common form of human <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> (CMD) is caused by mutations in the laminin-alpha2 gene </plain></SENT>
<SENT sid="1" pm="."><plain>Loss of laminin-alpha2 function in this <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> type 1A form of CMD results in neuromuscular dysfunction and, often, early <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Laminin-alpha2-deficient skeletal muscles in both humans and mice show signs of muscle cell <z:hpo ids='HP_0011420'>death</z:hpo> by <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>To examine the significance of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in CMD1A pathogenesis, we determined whether pathogenesis in laminin-alpha2-deficient (Lama2(-/-)) mice could be ameliorated by inhibiting <z:mpath ids='MPATH_3'>apoptosis</z:mpath> through either (a) inactivation of the proapoptosis protein Bax or (b) overexpression of the antiapoptosis protein Bcl-2 from a muscle-specific transgene </plain></SENT>
<SENT sid="4" pm="."><plain>We found that both of these genetic interventions produced a several-fold increase in the lifespan of Lama2(-/-) mice </plain></SENT>
<SENT sid="5" pm="."><plain>Bax inactivation also improved postnatal growth rate and myofiber histology and decreased fixed <z:hpo ids='HP_0001371'>contractures</z:hpo> of Lama2(-/-) mice </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, Bcl-2 family-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> contributes significantly to pathogenesis in the mouse model of CMD1A, and antiapoptosis therapy may be a possible route to amelioration of neuromuscular dysfunction due to laminin-alpha2 deficiency in humans </plain></SENT>
</text></document>